Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have received a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $30.2727.

A number of research firms have issued reports on BCAX. Wells Fargo & Company raised their target price on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Bank of America initiated coverage on Bicara Therapeutics in a report on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price on the stock. Morgan Stanley upped their price target on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th.

Bicara Therapeutics Trading Up 1.8%

BCAX stock opened at $20.00 on Thursday. Bicara Therapeutics has a twelve month low of $8.48 and a twelve month high of $24.25. The company has a market capitalization of $1.31 billion, a P/E ratio of -7.19 and a beta of -0.53. The firm has a 50 day simple moving average of $21.48 and a 200-day simple moving average of $18.72.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, research analysts predict that Bicara Therapeutics will post -3.48 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $20.29, for a total value of $253,625.00. Following the sale, the chief operating officer directly owned 191,641 shares in the company, valued at $3,888,395.89. The trade was a 6.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $23.61, for a total transaction of $354,150.00. Following the completion of the sale, the chief executive officer owned 362,152 shares in the company, valued at $8,550,408.72. The trade was a 3.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 141,183 shares of company stock valued at $2,895,572 over the last quarter. Company insiders own 13.80% of the company’s stock.

Institutional Trading of Bicara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in BCAX. Legal & General Group Plc raised its holdings in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics during the 4th quarter worth about $45,000. Larson Financial Group LLC raised its holdings in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.